Escozine Immunapen drops are venom based immune boosters that contain a patented polarized solution of Rhopalurus princeps scorpion venom. It is derived from a proprietary formulation found in its lead drug candidate Escozine, which includes a small molecular peptide found in scorpions that is then polarized through a patented process. The formulation is designed to enhance the user’s immune system while providing an energy booster that increases the overall quality of life. Its new and improved pen design is easy-to-use and can be carried on the go.
Venom therapies and treatments have been used for centuries by indigenous people and now have been widely adopted by the medical community as treatments to aid in reducing inflammation, pain and modulating immune response. Promoters of this product claim that Escozine Immunapen drops;
- Focuses on full immune health and function
- Helps to improve energy
- Helps to promote more restful sleep
Currently, animal venom components are being used as valuable and powerful pharmacological tools. Venom derived-drugs have been produced by the pharmaceutical industry since the 1970’s. Current pharmaceuticals utilize snake, scorpion, snail, and sea anemone venom components. These highly regarded medicines are used to treat cancer, high blood pressure, auto immune disease, MS and HIV.
Polarized Active Ingredients: Rhopalurus princeps venom-3x Silica-30C
Inactive Ingredients: Medical-grade Distilled Water.
Escozine Immunapen drops are produced by Medolife Rx, Inc. (“Medolife”), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc.
How Escozine Immunapen Drops Work
The Rhopalurus princeps venom contains a small molecular peptide that can pass through the blood-brain barrier in the body. Four small molecular peptides in the venom can attack various diseases in humans. To do this, it blocks small‐conductance chloride, sodium, potassium and calcium ion channels, and it also binds preferentially to abnormal and cancerous cells, leaving the normal cells intact. Medolife holds exclusive rights to the Rhopalurus princeps scorpion per the agreement signed with the Ministry of Environment and Natural Resources of the Dominican Republic.
How to Use Medolife RX Escozine Immunapen
Watch this video:
Can Escozine Immunapen drops cure COVID-19?
No, there is currently no evidence to suggest that COVID-19 can be cured by using Escozine Immunapen drops despite its proven ability to improve immune function. Your immune system consists of a complex collection of cells, processes, and chemicals that constantly defends your body against invading pathogens, including viruses, toxins, and bacteria. Keeping your immune system healthy with medication like Escozine Immunapen drops can help in preventing infection and disease like COVID-19.
In a recent study, a total of 400 patients in the Dominican Republic – where, a majority tested positive for COVID-19, and a small portion were COVID-19 symptomatic even though they tested negative for COVID-19 – reported a 100 percent improvement in symptoms after being administered Escozine. Many of the patients participating in the study reported severe COVID-19 symptoms, such as difficulty breathing, pain and high fever, which Escozine was able to relieve within 5 days of treatment.
Since the onset of the COVID-19 pandemic, there have seen a major increase in interest for immune system support in both the pharmaceutical and nutraceutical categories. Consumers are turning to products that promise to improve their immune systems more than ever during the ongoing COVID-19 pandemic, immune health is one of the top five reasons people take dietary supplements.
What are the possible side effects of Escozine Immunapen drops?
There is scarcity of information about the possible side effects of Immunapen drops. Allergic reactions to the venom in susceptible people may result in a potentially life-threatening reaction known as anaphylaxis. The World Allergy Organization estimates that 1% to 7% of the general population have allergic reactions to insect venoms.
